Interferon regulatory factor‐3 activation, hepatic interferon‐stimulated gene expression, and immune cell infiltration in hepatitis C virus patients

Interferon regulatory factor‐3 (IRF‐3) activation directs α/β interferon production and interferon‐stimulated gene (ISG) expression, which limits virus infection. Here, we examined the distribution of hepatitis C virus (HCV) nonstructural 3 protein, the status of IRF‐3 activation, and expression of IRF‐3 target genes and ISGs during asynchronous HCV infection in vitro and in liver biopsies from patients with chronic HCV infection, using confocal microscopy and functional genomics approaches. In general, asynchronous infection with HCV stimulated a low‐frequency and transient IRF‐3 activation within responsive cells in vitro that was associated with cell‐to‐cell virus spread. Similarly, a subset of HCV patients exhibited the nuclear, active form of IRF‐3 in hepatocytes and an associated increase in IRF‐3 target gene expression in hepatic tissue. Moreover, ISG expression profiles formed disease‐specific clusters for HCV and control nonalcoholic fatty liver disease patients, with increased ISG expression among the HCV patients. We identified the presence of T cell and plasmacytoid dendritic cell infiltrates within all biopsy specimens, suggesting they could be a source of hepatic interferon in the setting of hepatitis C and chronic inflammatory condition. Conclusion: These results indicate that HCV can transiently trigger IRF‐3 activation during virus spread and that in chronic HCV, IRF‐3 activation within infected hepatocytes occurs but is limited. (HEPATOLOGY 2007.)

[1]  M. Shiffman Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  H. Rosen,et al.  Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease , 2004, Hepatology.

[3]  N. Horiike,et al.  Decreased interferon‐α production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C , 2004, Clinical and experimental immunology.

[4]  M. Ruzek,et al.  Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. , 1998, Advances in experimental medicine and biology.

[5]  M. Gale,et al.  Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.

[6]  B. Pulendran,et al.  Dendritic cells at the host-pathogen interface , 2006, Nature Immunology.

[7]  S. Akira,et al.  Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2 , 2007, Proceedings of the National Academy of Sciences.

[8]  S. Akira,et al.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. , 2006, The Journal of clinical investigation.

[9]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[10]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[11]  C. Rice,et al.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. , 2005, The Journal of infectious diseases.

[12]  A. Dolganiuc,et al.  Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. , 2006, Journal of immunology.

[13]  Charles M. Rice,et al.  Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication , 2002, Journal of Virology.

[14]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[15]  S. Lemon,et al.  Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I , 2005, Journal of Virology.

[16]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[17]  C. McCaig,et al.  Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. , 2006, The Journal of clinical investigation.

[18]  T. Liang,et al.  Robust Production of Infectious Hepatitis C Virus (HCV) from Stably HCV cDNA-Transfected Human Hepatoma Cells , 2005, Journal of Virology.

[19]  M. Katze,et al.  Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers , 2003, Hepatology.

[20]  S. Lemon,et al.  Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Dolganiuc,et al.  Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-α and Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection1 , 2006, The Journal of Immunology.

[22]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[23]  S. Lemon,et al.  Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-β Production in Hepatocytes* , 2005, Journal of Biological Chemistry.

[24]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[25]  M. Gale,et al.  Functional and Therapeutic Analysis of Hepatitis C Virus NS3·4A Protease Control of Antiviral Immune Defense* , 2007, Journal of Biological Chemistry.

[26]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[27]  R. Purcell,et al.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Lemon,et al.  Intrahepatic gene expression profiles and alpha‐smooth muscle actin patterns in hepatitis C virus induced fibrosis , 2005, Hepatology.

[29]  W. Cao,et al.  Innate immune functions of plasmacytoid dendritic cells. , 2007, Current opinion in immunology.

[30]  N. Horiike,et al.  Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. , 2004, Clinical and Experimental Immunology.

[31]  Stanley M Lemon,et al.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Ralf Bartenschlager,et al.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus , 2005, Nature.

[33]  William M. Lee,et al.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[35]  Luca Mascitelli,et al.  Viral hepatitis C , 2004, The Lancet.

[36]  J. Hiscott,et al.  Transcriptional Profiling of Interferon Regulatory Factor 3 Target Genes: Direct Involvement in the Regulation of Interferon-Stimulated Genes , 2002, Journal of Virology.